doi: 10.1111/bph.13540 82 Clinical review(S)
Results from the ACHIEVE-1 trial showed that orforglipron led to robust efficacy outcomes across multiple endpoints: Weight Loss Observed: Orforglipron doses of 3 mg, 12 mg, and 36 mg were tested, with the highest dose (36 mg) resulting in the greatest weight loss
The absence of stretch marks or loose skin is a reliable predictor of healthy skin firmness
A special thanks to the head of the metabolic kitchen at my old department (now Department of Nutrition, Exercise and Sports), Charlotte Kostecki, for her invaluable creativity and support, and to my former PA Tina Cuthbertson for making it possible to be head of the department and still conducting research
Young professionals who face daily stress and environmental exposure may explore these treatments as part of a broader self-care routine
Most of the GLP-1 drugs studied in this group, of which there are several, remain largely under patent protection